KODAK  EK BUYS STAKE IN ENZON  ENZN ROCHESTER NY MARCH 5 EASTMAN KODAK CO SAID IT HAS ACQUIRED AN 187 PCT EQUITY INTEREST IN ENZON INC A PHARMACEUTICAL COMPANY SPECIALIZING IN PROTEIN THERAPY KODAK SAID IT SECURED WORLDWIDE MARKETING RIGHTS FOR THREE OF ENZON'S PEG ENZYMES USED IN THE TREATMENT OF OXYGEN TOXICITY DISORDERS HYPERURICEMIA AND GOUT THE COMPANY SAID IT ACQUIRED TWO MLN ENZON SHARES FOR 15 MLN DLRS WITH LOANS TO ENZON OF TWO MLN DLRS AND INTEREST OF 30000 DLRS CREDITED AGAINST THE PURCHASE PRICE KODAK SAID THE DRUGS COVERED BY THE MARKETING RIGHTS ARE IN INITIAL STAGES OF THE US FOOD AND DRUG ADMINISTRATION APPROVAL PROCESS  IT SAID THE INVESTMENT SHOULD PROVIDE THE NECESSARY CAPITAL TO COMPLETE THE FDA REVIEW PROCESS AND PROVIDE A MARKETING OUTLET FOR THE DRUGS THE DRUGS ARE PEG SUPEROXIDE DISDMUTASE AND PEG CATALASE FOR USE AGAINST OXYGEN TOXICITY DISORDERS THAT CAUSE THE OFTEN FATAL TISSUE DAMAGE ASSOCIATED WITH SEVERE BURNS ORGAN TRANSPLANTS HEART ATTACKS AND TRAUMA AND PEG URICASE FOR TREATMENT OF GOUT AND OTHER CONDITIONS CAUSED BY THE BUILDUP OF HIGH LEVELS OF URIC ACID IN THE BODY   